Early Alzheimer’s Treatment Shows Targeted Benefits Only for APOE4 Patients

New analysis suggests valiltramiprosate may help slow decline in a select high-risk group

Valiltramiprosate, an oral investigational Alzheimer’s therapy, did not meet its primary endpoint in a phase III trial of patients with early symptomatic disease. However, a prespecified subgroup analysis found that people with mild cognitive impairment who carried two copies of APOE4 experienced slower cognitive decline and reduced hippocampal atrophy …